Canbex lead compound VSN16R in Phase II clinical testing for the treatment of spasticity in people with multiple sclerosis.


VSN16R is in Phase II testing to determine whether it relieves spasticity in people with MS. Spasticity consists of stiffness and uncontrollable movements of limbs and torso. The trial is being carried out at major medical centres in the UK.

For detailed medical information about the trial, click here